Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn’s Disease: A Canadian Multi-Centre Observational Cohort Study

摘要

BackgroundUstekinumab (UST), an anti-IL12/23 inhibitor is indicated for moderate-to-severe Crohn’s disease (CD). However, it is unclear if patients treated with UST are at increased risk for postoperative complications.